A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC) Meeting Abstract

Industry Collaboration

cited authors

  • Fakih, M. G.; Tejani, M.; Ren, X.; Landes, D.; Werneke, S.; Curtis, K. K.; Hecht, J. R.

authors

Publication Date

  • September 1, 2022

webpage

published in

category

start page

  • S735

end page

  • S735

volume

  • 33

issue

  • 7